Diabetic Nephropathy: How ACE Inhibitors and ARBs Protect Kidneys and Control Protein

Diabetic nephropathy isn’t just a complication of diabetes-it’s the leading cause of kidney failure worldwide. If you have diabetes and your kidneys are leaking protein, your body is sending a clear signal: something’s wrong. The good news? Two classes of medications-ACE inhibitors and ARBs-have been proven to slow this damage, reduce protein in the urine, and protect kidney function for decades. But many patients never get the full benefit, not because the drugs don’t work, but because they’re not used the way they were meant to be.

What Is Diabetic Nephropathy?

Diabetic nephropathy happens when high blood sugar damages the tiny filtering units in your kidneys, called glomeruli. Over time, these filters become leaky, allowing protein-especially albumin-to escape into your urine. This is called albuminuria. When it becomes persistent (confirmed on two tests at least three months apart), it’s a sign that kidney damage has started. Left unchecked, this can lead to kidney failure, dialysis, or transplant.

It’s not just about kidney health. People with diabetic nephropathy have a much higher risk of heart attacks, strokes, and early death. That’s why managing it isn’t optional-it’s critical.

How ACE Inhibitors and ARBs Work

These drugs don’t just lower blood pressure. They target the root of the problem: the renin-angiotensin-aldosterone system, or RAAS. When this system is overactive in diabetes, it increases pressure inside the kidney’s filtering units. That pressure forces more protein out and speeds up scarring.

ACE inhibitors is a class of drugs that block the enzyme that turns angiotensin I into angiotensin II, a powerful constrictor of blood vessels. Angiotensin-converting enzyme inhibitors include drugs like lisinopril, enalapril, and ramipril.

ARBs is a class of drugs that block the receptor that angiotensin II binds to, preventing its harmful effects. Angiotensin II receptor blockers include losartan, valsartan, and irbesartan.

Both reduce pressure inside the glomeruli. That means less protein leaks out. And less protein in the urine means slower kidney damage. This effect is independent of blood pressure lowering. Even if your blood pressure is normal, these drugs still help-if you have protein in your urine.

Who Should Take Them?

The guidelines are clear. If you have diabetes and:

• High blood pressure, or
• Albumin in your urine (UACR ≥300 mg/g), or
• An estimated glomerular filtration rate (eGFR) below 60 mL/min/1.73 m²

you should be on an ACE inhibitor or ARB. The American Diabetes Association (ADA) 2025 Standards of Care give this a strong recommendation (Level B evidence). It’s not a "maybe." It’s standard care.

Even if you’re not hypertensive, but have severely increased albuminuria, you still benefit. The RENAAL and IDNT trials showed that ARBs like losartan and irbesartan cut the risk of progressing to end-stage kidney disease by 25-30% in type 2 diabetes patients with heavy proteinuria.

Dosing Matters-More Isn’t Just Better, It’s Necessary

This is where things go wrong in real-world practice. Many doctors start patients on low doses because they’re afraid of side effects. But the studies that proved these drugs work? They used maximal tolerated doses.

For example:

• Captopril for diabetic nephropathy: 25 mg three times daily
• Enalapril: 10-40 mg daily
• Ramipril: 5-20 mg daily
• Losartan: 50-100 mg daily
• Irbesartan: 150-300 mg daily

Yet, in clinics, patients are often stuck on half-doses. Why? Because doctors see a rise in serum creatinine and assume the drug is hurting the kidneys. It’s not. A creatinine increase of up to 30% is a normal, expected response-it means the drug is working by reducing pressure inside the kidney. Stopping the drug because of this is one of the biggest mistakes in diabetes care.

The ADA explicitly says: Do not discontinue ACE inhibitors or ARBs for a creatinine rise under 30% unless there’s volume depletion or another clear cause. Failing to use these drugs at full dose is suboptimal care.

Why You Shouldn’t Combine ACE Inhibitors and ARBs

You might think, "If one is good, two must be better." But that’s not true here.

The VA NEPHRON-D, ONTARGET, and ALTITUDE trials all tested combining ACE inhibitors with ARBs-or adding a direct renin inhibitor like aliskiren. The results? No extra kidney protection. Just more danger.

Combining these drugs increases the risk of:

• Hyperkalemia (dangerously high potassium)-risk doubles or triples
• Acute kidney injury-risk increases up to two-fold
• Low blood pressure and dizziness

There’s no benefit. Only harm. So if you’re on one, don’t add the other. Stick with the best single agent at the highest tolerated dose.

Other Medications to Avoid or Use Carefully

Some common drugs can make kidney damage worse when used with ACE inhibitors or ARBs.

• NSAIDs (like ibuprofen, naproxen): These reduce blood flow to the kidneys. When paired with RAAS blockers, they can cause sudden kidney failure, especially in older adults or those with existing kidney disease.
• Loop diuretics (furosemide, torsemide): While sometimes needed for fluid overload, they can worsen potassium and creatinine changes when combined with ACE/ARBs. Use only if necessary and monitor closely.

Also, avoid NSAIDs entirely if you have diabetes and kidney disease. Use acetaminophen for pain instead.

What About Newer Drugs Like SGLT2 Inhibitors?

Drugs like empagliflozin and dapagliflozin have shown powerful kidney protection in recent trials. But here’s the key point: all major studies tested them in patients who were already on ACE inhibitors or ARBs at maximum doses.

That means these newer drugs don’t replace ACE inhibitors or ARBs-they work alongside them. If you’re not on an ACE inhibitor or ARB, you’re missing the foundation. SGLT2 inhibitors are a powerful addition, not a substitute.

The same goes for nonsteroidal MRAs like finerenone. They add benefit, but only after RAAS blockade is optimized.

Why Many Patients Still Don’t Get These Drugs

Studies show only 60-70% of people with diabetes and kidney disease are even prescribed an ACE inhibitor or ARB after diagnosis. Why?

• Doctors fear creatinine spikes and stop the drug too soon
• Patients don’t feel symptoms, so they don’t see the need
• Cost or access issues, especially for brand-name versions
• Confusion about which drug to pick

The result? Delayed treatment. Progressing kidney damage. More hospitalizations. More dialysis.

Protein Control Is the Goal

Reducing protein in the urine isn’t just a lab number-it’s a sign that your kidneys are healing. The goal isn’t to get proteinuria to zero. It’s to get it as low as possible. Even a 30-50% reduction in albuminuria cuts the risk of kidney failure by 30-40%.

That’s why consistent use of ACE inhibitors or ARBs at full dose matters more than perfect blood sugar control alone. You can have HbA1c at 6.8% and still lose kidney function if proteinuria isn’t controlled.

What If You Can’t Tolerate Them?

Some people develop a persistent cough with ACE inhibitors. Others get low blood pressure or high potassium. In those cases:

• Switch to an ARB-they have fewer side effects
• If you can’t take either, use a calcium channel blocker (like amlodipine) or a thiazide diuretic as an alternative
• But never leave the RAAS system unblocked if you have proteinuria. Find a tolerable option.

There’s no perfect drug. But there’s always a better option than doing nothing.

Final Takeaway

Diabetic nephropathy is preventable. But only if you act early and use the right tools the right way. ACE inhibitors and ARBs are not optional add-ons. They’re the first line of defense. And they only work if you take them at the dose proven in trials-not the dose that feels safe in practice.

Don’t stop because your creatinine went up. Don’t skip because you feel fine. Don’t combine them with other RAAS blockers. And don’t wait for symptoms to appear before acting.

The science is solid. The guidelines are clear. The question isn’t whether you need these drugs. It’s whether you’re taking them enough.

For those managing diabetes, kidney protection isn’t a side benefit-it’s the priority. ACE inhibitors and ARBs are time-tested, effective, and underused. Use them right, and you can keep your kidneys working for years longer.